Camizestrant results ‘pivotal moment in breast cancer care’

Positive results from the SERENA-6 Phase III trial have shown that AstraZeneca’s (LSE: AZN) camizestrant alongside a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) led to a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS). 

The trial evaluated switching to the camizestrant combination versus continuing standard-of-care treatment with an aromatase inhibitor (AI) (anastrozole or letrozole) in combination with a CDK4/6 inhibitor in the first-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors have an emergent ESR1 mutation.

These results were presented during the Plenary Session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in The New England Journal of Medicine.